Evidence map›Paper›PMID 30617849›Full record

Trial reportJournal of neurovirology2019

Self-initiated continuation of and adherence to HIV pre-exposure prophylaxis (PrEP) after PrEP demonstration project roll-off in men who have sex with men: associations with risky decision making, impulsivity/disinhibition, and sensation seeking.

Martin Hoenigl, Erin Morgan, Donald Franklin, Peter L Anderson, Elizabeth Pasipanodya, Matthew Dawson, Marvin Hanashiro, Eric E Ellorin, Jill Blumenthal, Robert Heaton and 3 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of neurovirology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention.Journal of acquired immune deficiency syndromes (1999) · 2019
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Martin HoeniglUniversity of California San Diego (UCSD), San Diego, CA, USA. mhoenigl@ucsd.edu.ORCID 0000-0002-1653-2824
Erin MorganUniversity of California San Diego (UCSD), San Diego, CA, USA.
Donald FranklinUniversity of California San Diego (UCSD), San Diego, CA, USA.
Peter L AndersonUniversity of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Elizabeth PasipanodyaUniversity of California San Diego (UCSD), San Diego, CA, USA.
Matthew DawsonUniversity of California San Diego (UCSD), San Diego, CA, USA.
Marvin HanashiroUniversity of California San Diego (UCSD), San Diego, CA, USA.
Eric E EllorinUniversity of California San Diego (UCSD), San Diego, CA, USA.
Jill BlumenthalUniversity of California San Diego (UCSD), San Diego, CA, USA.
Robert HeatonUniversity of California San Diego (UCSD), San Diego, CA, USA.
David J MooreUniversity of California San Diego (UCSD), San Diego, CA, USA.
Sheldon R MorrisUniversity of California San Diego (UCSD), San Diego, CA, USA.
California Collaborative Treatment Group (CCTG) 601 Team
University of California San Diego · USMedical University of Graz · AT

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAVID J MOORE · 2001 to 2026
$50.4M
Translational Methamphetamine AIDS Research Center (TMARC)P50DA026306 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GRANT, IGOR · 2009 to 2018
$33.9M
Primary Infection Resource Consortium (PIRC)R24AI106039 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2013 to 2021
$23.1M
Interdisciplinary Research Fellowship in NeuroAIDSR25MH081482 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MARIANA CHERNER · 2007 to 2026
$5.2M
Improving Antiretroviral Management for HIVK24AI064086 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HAUBRICH, RICHARD H · 2006 to 2015
$1.8M
Perception of repeated negative HIV test results in young men who have sex with menR21MH113477 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HOENIGL, MARTIN · 2018 to 2019
$441k
NCATS NIH HHS UL1 TR001442NIAID NIH HHS K24 AI064086NIAID NIH HHS P30 AI036214NIAID NIH HHS R24 AI106039NIDA NIH HHS P50 DA026306NIMH NIH HHS P30 MH062512NIMH NIH HHS R21 MH113477NIMH NIH HHS R25 MH081482
6 · The paper itself

Abstract

The objective of this study was to examine differences in the levels of risky decision making and other frontal system behavior constructs in relation to self-initiated continuance of HIV pre-exposure prophylaxis (PrEP) and PrEP adherence outcomes among men who have sex with men (MSM) following completion of a clinical PrEP trial. At the last PrEP trial visit, study provided PrEP was discontinued and participants were navigated to the community for PrEP continuation. In this cross-sectional analysis, 84/187 (45%) MSM who completed a prospective observational post-PrEP trial follow-up visit at the University of California San Diego were included. PrEP adherence was measured using dried blood spot tenofovir diphosphate (TFV-DP) levels. Risky decision making was assessed using the Iowa Gambling Task (IGT) and the Balloon Analogue Risk Task (BART), while impulsivity/disinhibition, sensation seeking, and substance use were assessed via standardized self-report questionnaires. A total of 58/84 (69%) of MSM who completed the 12-month post-study visit continued PrEP. Of those, n = 46 (79%) reached TFV-DP levels associated with adequate adherence. Individuals who elected to continue PrEP 12 months post-trial had riskier decision making on BART, but less impulsivity/disinhibition compared to individuals who did not continue PrEP. Neither risky decision making nor impulsivity/disinhibition/sensation seeking nor substance use correlated with PrEP adherence. Our findings suggest that those with risky decision making may have greater insight into their HIV risks, and therefore be more likely to continue to use PrEP. However, elevated impulsivity/disinhibition, indicative of greater neurobehavioral alterations, was negatively associated with PrEP continuance and is a potential target for future interventions to help people link to PrEP.

Indexed as

Decision MakingImpulsive BehaviorRisk-TakingAdultAgedAnti-HIV AgentsHIV InfectionsHomosexuality, MaleHumansMaleMedication AdherenceMiddle AgedPre-Exposure ProphylaxisSexual and Gender MinoritiesTenofovirAnti-HIV AgentsTenofovirAdherenceDried blood spotSensation seekingSeroconversionStimulant substance use

Identifiers

PMID30617849
PMCPMC6612450
OpenAlexW2909494846

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.